Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2008

View Archived Issues

Novel series of histamine H3 receptor inverse agonists disclosed by Banyu and Merck

Drospirenone evaluated as antiadipogenic agent in preclinical studies

Phase I studies demonstrate proof-of-concept for REG1 anticoagulation system

AdVEGF121 BIOBYPASS gene therapy not beneficial in advanced coronary artery disease

DU-176b prevents venous thromboembolism in patients undergoing total hip replacement

Orexo and Boehringer extend research collaboration in pain and inflammation

Cubist presents update on acute care product pipeline

Recent patents describe new antipsychotic and antidepressant agents

Nabi and the NIAID enter collaboration to advance PentaStaph S. aureus vaccine

Novel anticancer agents disclosed in recent patent literature

Novel treatment options for gastrointestinal disorders reported in recent patents

Allergan and Asterand sign exclusive license agreement for preclinical compounds for eye diseases

ImVision starts enrollment in phase I IVN-201 trial for cat dander allergy

Proteon receives FDA fast track designation for PRT-201

TopoTarget reports phase II belinostat data in cutaneous lymphomas and ovarian cancer

FDA grants priority review to Novartis' Afinitor and MAA filed with EMEA and Swissmedic

Addex has reported results from phase II studies of ADX-10059

Hana achieves response criteria to proceed to full enrollment in rALLy clinical trial of Marqibo

Cellzome and GSK sign worldwide strategic alliance for kinase-targeted therapeutics

Bayer signs licensing agreement with Nagasaki University to use tracers in PET in AD

CVBT opens first U.S. enrollment site in phase II clinical trial of FGF-1 in heart disease

RiskMetrics approves Roche's planned acquisition of Arius Research's outstanding shares and warrants

Pluristem reports results from preclinical safety studies in animals of PLX-PAD in CLI

Solvay acquires Innogenetics for EUR 200.7 million in cash

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...